Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases

New England Journal of Medicine

Volumn 335, Issue 24, 1996, Pages 1785-1791

  Hortobagyi, Gabriel N ^a   Theriault, Richard L ^a   Porter, Lester ^b   Blayney, Douglas ^c   Lipton, Allan ^d   Sinoff, Clive ^e   Wheeler, Helen ^f   Simeone, Joseph F ^g   Seaman, John ^h   Knight, Robert D ^h   Heffernan, Maika ^h   Reitsma, Dirk J ^h   Kennedy, Ian ⁱ   Allan, Simon G ^j   Mellars, Kathleen ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b SAINT THOMAS HOSPITAL   (United States)

^c ST VINCENT MEDICAL CENTER   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e NE Ontario Regional Cancer Center ^*  (Canada)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ WAIKATO HOSPITAL   (New Zealand)

^j PALMERSTON NORTH HOSPITAL   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CARCINOEMBRYONIC ANTIGEN; CREATININE; HYDROXYPROLINE; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MUSCLE WEAKNESS; OSTEOLYSIS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 10544228130     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199612123352401     Document Type: Article

References (27)

1. Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop 1970;73:8-32.
2. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985;12:251-70.
3. Fleisch H. Bisphosphonatcs: a new class of drugs in diseases of bone and calcium metabolism. In: Brunner KW, Fleisch H, Senn H-J, eds. Bisphosphonates and tumor osteolysis. Vol. 116 of Recent results in cancer research. Berlin, Germany: Springer-Verlag, 1989:1-28.
4. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993;19:79-103.
5. Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992;26: 1262-9.
6. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 1988;58:621-5.
7. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988;297:772-3.
8. Burckhardt P, Thiebaud D, Percy I., von Fliedner V. Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989;116:54-66.
9. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994;74:2949-55.
10. Dodwell DJ, Howell A, Morton A, Daley-Yates PT, Hoggarth CR. Pamidronate (APD) treatment of skeletal metastases from breast cancer. In: Rubens RD, ed. The management of bone metastases and hypercalcemia by osteoclast inhibition. Bern, Switzerland: Hogrefe & Huber, 1990:76-80.
11. Hacking A, Gudgeon CA, McNaughton D, Dent DM. Pamidronate (APD) as single infusion monotherapy in the treatment of bone metastases from breast cancer. In: Bijvoet OLM, Lipton A, eds. Osteoclast inhibition in the management of malignancy-related bone disorders. Bern, Switzerland: Hogrefe & Huber, 1991:45-53.
12. Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988.
13. The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6th ed. Boston: Little, Brown, 1964.
14. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
15. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981;34:585-97.
16. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, Switzerland. Cancer 1977;39:1289-94.
17. Mattsson W, von Eyben F, Hallsten L, Bjelkengren G. A phase II study of combined 5-fluorouracil and mitoinycin C in advanced breast cancer. Cancer 1982;49:217-20.
18. De Lena M, Brandi M, Logroscino A, Lorusso V, Paradiso A, Maiello E. Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in merastatic breast cancer: a pilot study. Tumori 1988;74: 57-63.
19. Carmo-Pereira J, Costa FO, Henriques E, Cantinho-Lopes MG, Godinho F, Sales-Luis A. Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma: a phase II study. Eur J Cancer Clin Oncol 1988;24:473-6.
20. Di Costanzo F, Gori S, Tonato M, et al. Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer. Cancer 1986;57:904-7.
21. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:560-71.
22. Parvinen L-M, Numminen S. Chemotherapy in advanced breast carcinoma: comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone. Acta Radiol Oncol 1985;24:391-4.
23. Muss HB, Richards F II, Jackson DV, et al. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association. Cancer 1982;50:2269-74.
24. Whitehouse JMA. Site-dependent response to chemotherapy for carcinoma of the breast. J R Soc Med 1985;78:Suppl 9:18-22.
25. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
26. van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991;27:544-9.
27. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer J Clin Oncol 1993;11:491-8.